Skip to content
Guavy Logo GUAVY
Sign up
Back to Guavy Wire
Stocks

RBC Capital Holds Firm on Beam Therapeutics Amid Significant Losses

Guavy AI Editorial Team
Instruments
AMGN
Share

RBC Capital analyst Luca Issi has maintained his Hold rating on Beam Therapeutics (BEAM), setting a price target of $26.00.

The company's latest earnings report, covering the quarter ending June 30, revealed a GAAP net loss of $122.68 million, compared to last year's revenue of $8.47 million and a GAAP net loss of $102.29 million.

According to TipRanks, Issi has an average return of -1.4% and a 39.55% success rate on recommended stocks, covering the Healthcare sector with focus on stocks such as Alnylam Pharma, Amgen, and Argenx Se.

More on Stocks

Stocks 6m ago

JPMorgan CEO Warns Market Leverage at 'Pretty High' Levels

Stocks 6m ago

JPMorgan Chase Surpasses Q2 Earnings Expectations

Stocks 10m ago

Capital One Offers Huge Rewards on Purchases Ahead of Expiration Deadline

Disclaimer: Guavy is a data and market intelligence provider, not an investment advisor. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Guavy Logo GUAVY

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

Navigate

Markets

Resources

© 2026 Guavy Inc

Terms Privacy Policy